Does semaglutide work? what the clinical evidence shows. - Reddit

What does semaglutide actually do in the body?

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. GLP-1 is a hormone the gut naturally releases in response to food. It signals the brain to reduce appetite, slows the rate at which the stomach empties (gastric motility), and improves insulin secretion in response to meals.

Semaglutide mimics and amplifies these effects. In clinical doses for weight management (2.4 mg weekly), patients consistently report reduced hunger, fewer food cravings, and a sense of fullness with smaller portions. For people whose biology drives persistent overeating despite conscious effort to restrict calories, this pharmacological appetite suppression changes the equation substantially.

It is important to understand what semaglutide is not: it is not a metabolism booster, it does not significantly increase resting energy expenditure, and it is not a fat-burning drug in the classical sense. Its primary mechanism is appetite regulation. Weight loss follows from eating less, not from burning more.

What does the STEP trial data actually show?

The Semaglutide Treatment Effect in People with obesity (STEP) program is a series of five major randomized, placebo-controlled trials that represent the most rigorous evidence base for semaglutide 2.4 mg in weight management. Here is what they found:

• STEP 1: Adults with overweight or obesity (no type 2 diabetes) who received semaglutide 2.4 mg weekly achieved a mean weight reduction of 14.9% over 68 weeks. The placebo group lost 2.4%. Nearly 86% of semaglutide participants lost at least 5% of body weight; 69% lost at least 10%; and 50% lost at least 15%.
• STEP 2: Adults with type 2 diabetes achieved a mean weight loss of 9.6% — meaningful, but lower than STEP 1, which is consistent with what is known about how type 2 diabetes affects GLP-1 responsiveness.
• STEP 5: The two-year data confirmed sustained weight loss. Patients maintained approximately 15.2% weight reduction at 104 weeks, demonstrating that the effect is durable with continued treatment, not just an early-response phenomenon.
• STEP 4: The discontinuation arm. Patients who stopped semaglutide at week 20 regained approximately two-thirds of their lost weight by week 68. This arm confirmed that semaglutide is a maintenance therapy, not a one-time intervention.

To put these numbers in context: before the GLP-1 era, the most effective non-surgical pharmacotherapy for obesity produced average weight losses of 5–8%. Semaglutide at 2.4 mg roughly doubled that benchmark in a randomized controlled setting.

Who responds best to semaglutide — and who may see less effect?

Not everyone gets 15% weight loss from semaglutide. Several factors influence individual response:

• Diabetes status: Patients with type 2 diabetes consistently lose less weight than those without, across the STEP trial data. The underlying biology of insulin resistance appears to blunt GLP-1 response.
• Adherence and dose: Trial participants were supported with lifestyle counseling and regular follow-up. Real-world adherence is often lower, and the titration schedule is sometimes interrupted by GI side effects. Missing doses or failing to reach the 2.4 mg maintenance dose reduces outcomes.
• Baseline dietary habits: Semaglutide reduces appetite; it does not dictate food choice. Patients who continue to consume high-calorie, low-nutrient foods in smaller portions may see less fat loss and more lean mass loss. Adequate protein intake is important.
• GI tolerability: Nausea, vomiting, and constipation affect a meaningful proportion of patients, particularly in the first four to eight weeks. For those who cannot tolerate the titration, outcomes are limited by dose ceiling.

Does the weight come back when you stop semaglutide?

STEP 4’s discontinuation data generated significant media coverage because it seemed to suggest that weight comes back when semaglutide is stopped. The correct framing is more nuanced.

Semaglutide manages a chronic condition — excess weight — the same way antihypertensives manage blood pressure. If you stop the medication, the biological drivers of weight regain (elevated appetite, altered satiety signaling) return. The drug was managing those drivers while you were taking it; it was not correcting the underlying biology permanently.

This reframing has clinical implications. Most endocrinologists and obesity medicine specialists now treat GLP-1 therapy as a long-term intervention, similar to other chronic-disease medications. Patients who stop after reaching a goal weight without establishing sustainable dietary patterns often regain weight. Those who maintain the habits they built during treatment tend to do better.

Is compounded semaglutide the same molecule? What you need to know

Compounded semaglutide — prepared by licensed 503A pharmacies — contains the same active molecule that is the subject of the STEP trial data. The FDA-approved branded products (Ozempic at 1 mg and Wegovy at 2.4 mg) and compounded semaglutide are not the same product: compounded medications are not FDA-approved and are not prepared under the same quality controls as brand-name products.

What is the same is the active molecule and the mechanism of action. The clinical evidence cited above applies to the semaglutide molecule; it was not conducted on branded packaging.

For patients accessing compounded semaglutide: the quality of the compounding pharmacy matters significantly. A licensed 503A pharmacy in the United States compounds under USP standards with licensed pharmacists. Products from unregulated overseas sources or gray-market suppliers do not offer these assurances — and contamination, incorrect concentration, and labeling errors are documented risks in that market.

The bottom line

Does semaglutide work? By the standards of randomized controlled evidence, it is one of the most effective non-surgical weight management tools ever studied. Average weight loss of 15% in a 68-week placebo-controlled trial is a benchmark that predecessors in the drug class did not approach.

Does semaglutide work for everyone? No. Individual response varies, and the drug requires consistent use, adequate dose titration, and supportive dietary habits to deliver its potential. It also requires staying on the medication — stopping reliably results in weight regain for most patients.

The right clinical context is a supervised program where a licensed clinician reviews your history, sets a realistic titration schedule, and monitors your progress. That supervised structure is what separates the outcomes in the STEP trials from what many patients experience when they obtain semaglutide without clinical support.

Frequently asked questions